Is natalizumab overshooting its rebound?

Neurology

Volumn 70, Issue 13 PART 2, 2008, Pages 1073-1074

  Fox, Robert J ^a   Kappos, Ludwig ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; NATALIZUMAB; NEUTRALIZING ANTIBODY; PLACEBO; ROQUINIMEX; VERY LATE ACTIVATION ANTIGEN 4;

BRAIN DAMAGE; CLINICAL TRIAL; DISEASE ACTIVITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG WITHDRAWAL; EDITORIAL; HUMAN; LEUKOENCEPHALOPATHY; LONG TERM CARE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REBOUND; RELAPSE; SHORT COURSE THERAPY;

EID: 41549118974     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000306415.37679.5a     Document Type: Editorial

References (10)

1. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910.
2. Vellinga MM, Castelijns JA, Barkhof F, Uitdehaag BMJ, Polman CH. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology 2008;70:1150-1051.
3. Tan IL, Lycklama a Nijeholt GJ, Polman CH, Ader HJ, Barkhof F. Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials. Mult Scler 2000;6:99-104.
4. Wolinsky JS, Narayana PA, Noseworthy JH, et al. Linomide in relapsing and secondary progressive MS: part II: MRI results. MRI analysis. Neurology 2000;54:1734-1741.
5. Tubridy N, Behan PO, Capildeo R, et al. The effect of anti-alpha4 integrin antibody on brain lesion activity in MS: The UK Antegren Study Group. Neurology 1999;53:466-472.
6. Theien BE, Vanderlugt CL, Nickerson-Nutter C, et al. Differential effects of treatment with a small-molecule VLA-4 antagonist before and after onset of relapsing EAE. Blood 2003;102:4464-4471.
7. O'Connor PW, Goodman A, Willmer-Hulme AJ, et al. Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. Neurology 2004;62:2038-2043.
8. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003;348:15-23.
9. O'Connor PW, Goodman A, Kappos L, et al. Results of clinical and magnetic resonance imaging analyses following cessation of natalizumab dosing in patients with multiple sclerosis. Mult Scler 2006;12(suppl 1):S17.
10. Calabresi PA, Giovannoni G, Confavreux C, et al. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology 2007;69:1391-1403.